Translational Development Acquisition (TDAC) Consolidated Net Income (2024 - 2026)

Translational Development Acquisition has reported Consolidated Net Income for 3 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 10.13% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (up 331.06% YoY), and the FY2025 full-year result was $6.4 million, up 9059.65% from the prior year.
• Consolidated Net Income for Q1 2026 stood at $1.3 million, down from $1.5 million in the prior quarter.
• The five-year high for Consolidated Net Income was $1.7 million in Q3 2025, with the low at -$61283.0 in Q3 2024.
• Historically, Consolidated Net Income has averaged $937358.2 across 3 years, with a median of $1.4 million in 2025.
• Annual changes were most pronounced in 2025 — Consolidated Net Income surged 96440.77% — and 2026, when it dropped 10.13%.
• Translational Development Acquisition's Consolidated Net Income stood at -$8044.0 in 2024, then surged by 18381.24% to $1.5 million in 2025, then fell by 9.37% to $1.3 million in 2026.
• The last three Consolidated Net Income figures came in at $1.3 million (Q1 2026), $1.5 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.